Sep, 12 2017 23:37 JST

Source: Eisai

Eisai Selected for Fifth Consecutive Year of Membership in Dow Jones Sustainability Asia Pacific Index 2017


TOKYO, Sep, 12 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for a fifth consecutive year of membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI).

The DJSI family was jointly established between RobecoSAM AG (Switzerland) and S&P Dow Jones Indices LLC (United States) in 1999 as the first global SRI indices in the world and assesses the corporate sustainability performance of eligible member companies based on economic, environmental and social criteria. This year, the DJSI Asia Pacific has selected 152 companies leading the way in sustainability (72 of which are from Japan) from among the region's top 614 companies. Eisai received high scores particularly in categories such as Codes of Business Conduct, Product Quality and Recall Management, Labor Practice Indicators as well as Strategy to Improve Access to Drugs or Products.

In addition to the DJSI Asia Pacific, Eisai has been selected for the 16th consecutive year since 2002 as a member of the FTSE4Good Index Series, another global benchmark SRI index.

The Eisai Group's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Guided by this philosophy, Eisai will continue to develop innovative new drugs and make them available to patients around the world as early as possible to fulfill its social responsibility and secure the trust of stakeholders.


About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech, HealthCare

Copyright ©2017 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen
December 08 2017 13:57 JST
 
Eisai Submits Application for Expanded Indication Covering Hepatocellular Carcinoma for Anticancer Agent Lenvima in Taiwan
December 06 2017 16:31 JST
 
Eisai's Resubmitted NDA for Anticancer Agent Halaven Accepted in China
November 30 2017 08:41 JST
 
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting
November 24 2017 14:07 JST
 
Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN
November 20 2017 14:50 JST
 
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December
November 20 2017 14:28 JST
 
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease
November 06 2017 19:37 JST
 
Eisai's New Drug Application of Anticancer Agent Lenvatinib for Hepatocellular Carcinoma Accepted in China
October 31 2017 12:05 JST
 
Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer's Diesase
October 31 2017 10:27 JST
 
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab
October 24 2017 10:08 JST
 
More Press release >>

Latest Press Release


More Latest Release >>